• Naoyuki Kamatani, Shin Fujimori, Toshikazu Hada, Tatsuo Hosoya, Kenjiro Kohri, Toshitaka Nakamura, Takanori Ueda, Tetsuya Yamamoto, Hisashi Yamanaka, and Yuji Matsuzawa.
• Institute of Rheumatology, Tokyo Women's Medical University, Japan. kamatani@msb.biglobe.ne.jp
• J Clin Rheumatol. 2011 Jun 1; 17 (4 Suppl 2): S13-8.

BackgroundAllopurinol has been widely used for treatment of hyperuricemia, however, it may be associated with various adverse effects. Febuxostat is potentially a safe and efficacious alternative.ObjectivesFebuxostat or allopurinol was administered to patients with hyperuricemia including gout for 8 weeks to compare the efficacy and safety of these drugs.MethodsDoses of febuxostat and allopurinol were 10 and 100 mg/d, respectively, during a 12-day introduction period and were increased to 40 and 200 mg/d for the subsequent treatment period of 44 days.Results: The percent changes in serum uric acid levels after 8 weeks were -40.75% for the febuxostat group and -34.41% for the allopurinol group (P < 0.001, analysis of variance, closing testing procedure). The percentage of patients achieving serum uric acid levels 6.0 mg/dL or less after 8 weeks was 82.0% for the febuxostat group and 70.0% for the allopurinol group (P = 0.019, logistic regression analysis). Regarding safety, 213 adverse events were observed in the febuxostat group and 220 events in the allopurinol group. For 10 patients (8.2%) in the febuxostat group and 14 patients (11.6%) in the allopurinol group, association with the study drugs could not be ruled out. There were no severe adverse drug reactions in the febuxostat group other than a high frequency of gout attacks induced by the sudden reduction in blood uric acid levels during the early treatment period.ConclusionsFebuxostat at 40 mg/d demonstrated more potent hypouricemic effects than allopurinol at 200 mg/d, was efficacious regardless of medical history of gout, and is considered safe for treatment of hyperuricemia.

32 keywords...

hide…